Response to treatment ‐ medium term · patients with schizophrenia
Trifluoperazine showed no clear difference in response to treatment ‐ medium term compared with low‐potency antipsychotic drugs (low certainty).
1 finding from 1 review
Acceptability of treatment ‐ leaving the study early · patients with schizophrenia
Trifluoperazine showed no clear difference in leaving the study early: 1. Acceptability of treatment ‐ leaving… compared with low‐potency antipsychotic drugs (low certainty).
1 finding from 1 review
Adverse effects/events: at least 1 adverse effect ‐ as defined by individual studies. · patients with schizophrenia
Trifluoperazine showed no clear difference in adverse events: 1. General ‐ at least one adverse effect compared with low‐potency antipsychotic drugs (moderate certainty).
1 finding from 1 review
Adverse effects ‐ movement disorders ‐ At least one movement disorder · patients with schizophrenia
Trifluoperazine showed no clear difference in adverse events: 2.a. Specific ‐ movement disorders ‐ at least one… compared with low‐potency antipsychotic drugs (low certainty).
1 finding from 1 review
Death · patients with schizophrenia
1 finding from 1 review
Adverse effects: 1. Sedation · patients with schizophrenia
1 finding from 1 review
Quality of life · patients with schizophrenia
1 finding from 1 review
Global state ‐ clinical improvement ‐ medium term As defined by each study · patients with schizophrenia
TRIFLUOPERAZINE may leads to higher global state ‐ clinical improvement ‐ medium term As defined by each… compared with PLACEBO (low certainty).
1 finding from 1 review
Global state ‐ relapse or worsening ‐ medium term Numbers of participants experiencing relapse/worsening · patients with schizophrenia
TRIFLUOPERAZINE may leads to lower global state ‐ relapse or worsening ‐ medium term Numbers of… compared with PLACEBO (low certainty).
1 finding from 1 review
Mental state ‐ any clinically significant response in psychotic symptoms (as defined by each study) ‐ medium term Numbers of participants experiencing 'intensified symptoms' · patients with schizophrenia
It is very uncertain whether TRIFLUOPERAZINE changes mental state ‐ any clinically significant response in psychotic… compared with PLACEBO (very low certainty).
1 finding from 1 review
Leaving the study early · patients with schizophrenia
It is very uncertain whether TRIFLUOPERAZINE changes leaving the study early ‐ any reason ‐ medium term Number of… compared with PLACEBO (very low certainty).
1 finding from 1 review
Severe adverse effects ‐ short term Numbers of participants leaving the studies due to severe adverse effects · patients with schizophrenia
It is very uncertain whether TRIFLUOPERAZINE changes severe adverse effects ‐ short term Numbers of participants leaving… compared with PLACEBO (very low certainty).
1 finding from 1 review
Behaviour ‐ any clinically significant agitation or distress ‐ medium term As defined by each study · patients with schizophrenia
It is very uncertain whether TRIFLUOPERAZINE changes behaviour ‐ any clinically significant agitation or distress ‐… compared with PLACEBO (very low certainty).
1 finding from 1 review
Economic outcomes · patients with schizophrenia
1 finding from 1 review
Global state: Average endpoint global state score (clinically improved) (no data) · schizophrenia
1 finding from 1 review
Adverse effects: Clinically important general adverse effect (no data) · schizophrenia
1 finding from 1 review
Death: Suicide and natural causes (no data) · schizophrenia
1 finding from 1 review
Length of hospital stay · schizophrenia
1 finding from 1 review
Mental state: Average endpoint general mental state score (clinically improved) (no data) · schizophrenia
1 finding from 1 review
Leaving the study early · schizophrenia
1 finding from 1 review